Protocol Reference
BPC-157
BPC-157 — research context, not a human protocol
Set out what published research does and does not establish about BPC-157 administration, and why no human protocol can responsibly be summarised.
Not FDA ApprovedReviewed September 1, 2026
No established human dosing protocol exists for this compound. What follows describes the research context only — the conditions under which the compound has been studied, usually in animals or in vitro.
Research Context
- Source of this information
- BPC-157 is one of the most searched peptides online and one of the least supported by human protocol evidence. That contrast is the substance of this page.
- Evidence level
- Grade D — animal and in-vitro research; no adequate published human trials for musculoskeletal outcomes
- Population studied
- Rats and mice in the great majority of published studies. Early human work exists in inflammatory bowel disease only.
- Duration studied
- Animal studies typically ran days to weeks, matched to injury-model timelines.
- Route reported
- Animal studies used intraperitoneal, intramuscular, subcutaneous, oral and topical administration. Dosing in these studies is expressed per kilogram of animal body weight and is not transferable to people.
Protocol as Reported
- 01No established human dosing protocol exists.
- 02Published animal studies report doses in micrograms or nanograms per kilogram, administered by routes not used in human practice, in injury models with no human equivalent.
- 03Allometric conversion of rodent doses to human doses is not a validated basis for a research protocol and is not presented here as one.
- 04Widely circulated community schedules do not originate in published research and are not clinical standards.
Adverse Events Reported
- No systematic human safety dataset exists.
- Pro-angiogenic activity in animal models raises unresolved questions about behaviour in the presence of undiagnosed malignancy.
- Research-use-only material adds risks of misidentification, contamination and incorrect concentration.
Limitations
- Animal healing models predict human musculoskeletal outcomes poorly.
- A large share of the literature comes from a small number of affiliated groups, limiting independent replication.
- BPC-157 appears among substances the FDA has identified as raising significant safety concerns in compounding, and it is prohibited in sport.
Sources
- Narrative review
Stable gastric pentadecapeptide BPC 157: healing research review
- Regulatory document
FDA bulk drug substances nominated for use in compounding
Educational reference only. Peptide Atlas does not provide medical advice or individualised dosing guidance, and nothing on this page should be used to guide personal use.